
Bo Peng
Examiner (ID: 15510)
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, CQIC, 4171, 4111 |
| Total Applications | 343 |
| Issued Applications | 135 |
| Pending Applications | 38 |
| Abandoned Applications | 170 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16949454
[patent_doc_number] => 20210208145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR TRIPLE-NEGATIVE BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/207165
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207165
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/207165 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR TRIPLE-NEGATIVE BREAST CANCER | Mar 18, 2021 | Abandoned |
Array
(
[id] => 18352044
[patent_doc_number] => 20230140155
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/910544
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910544
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/910544 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Mar 10, 2021 | Pending |
Array
(
[id] => 17428437
[patent_doc_number] => 20220056145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => ANTI-CD39 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/197097
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17197097
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/197097 | ANTI-CD39 ANTIBODIES | Mar 9, 2021 | Abandoned |
Array
(
[id] => 16961580
[patent_doc_number] => 20210213079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/193511
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193511
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | Mar 4, 2021 | Pending |
Array
(
[id] => 18335588
[patent_doc_number] => 20230127536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => TARGETING TIM-3 AND LAG-3 RECEPTORS INDUCED BY CD44+ CD90+ CANCER STEM CELLS IN SMALL CELL LUNG CANCER
[patent_app_type] => utility
[patent_app_number] => 17/917956
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2982
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917956
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/917956 | TARGETING TIM-3 AND LAG-3 RECEPTORS INDUCED BY CD44+ CD90+ CANCER STEM CELLS IN SMALL CELL LUNG CANCER | Mar 3, 2021 | Pending |
Array
(
[id] => 18264641
[patent_doc_number] => 20230085883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/802124
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802124
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802124 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy | Mar 2, 2021 | Issued |
Array
(
[id] => 19121065
[patent_doc_number] => 11965036
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Bispecific antigen-binding constructs targeting HER2
[patent_app_type] => utility
[patent_app_number] => 17/184508
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 121
[patent_no_of_words] => 52180
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 216
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184508
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/184508 | Bispecific antigen-binding constructs targeting HER2 | Feb 23, 2021 | Issued |
Array
(
[id] => 18620452
[patent_doc_number] => 11753480
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Anti-SIRP-alpha antibodies and related methods
[patent_app_type] => utility
[patent_app_number] => 17/182081
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 27715
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17182081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/182081 | Anti-SIRP-alpha antibodies and related methods | Feb 21, 2021 | Issued |
Array
(
[id] => 18250677
[patent_doc_number] => 20230077716
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => ANTIBODIES PROTECTIVE AGAINST INFLUENZA B
[patent_app_type] => utility
[patent_app_number] => 17/798261
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798261
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/798261 | ANTIBODIES PROTECTIVE AGAINST INFLUENZA B | Feb 4, 2021 | Abandoned |
Array
(
[id] => 19503858
[patent_doc_number] => 12115256
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Targeted liposomal gemcitabine and methods thereof
[patent_app_type] => utility
[patent_app_number] => 17/165534
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 15690
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165534 | Targeted liposomal gemcitabine and methods thereof | Feb 1, 2021 | Issued |
Array
(
[id] => 17300918
[patent_doc_number] => 20210396757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA
[patent_app_type] => utility
[patent_app_number] => 17/160171
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15311
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17160171
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/160171 | COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA | Jan 26, 2021 | Abandoned |
Array
(
[id] => 16848166
[patent_doc_number] => 20210148911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => Methods and Diagnostics for Cancer Detection and Treatment Monitoring
[patent_app_type] => utility
[patent_app_number] => 17/159480
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14855
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159480
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159480 | Methods and Diagnostics for Cancer Detection and Treatment Monitoring | Jan 26, 2021 | Abandoned |
Array
(
[id] => 18195506
[patent_doc_number] => 20230049025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => ENGINEERED IMMUNE CELLS
[patent_app_type] => utility
[patent_app_number] => 17/759222
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759222
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/759222 | ENGINEERED IMMUNE CELLS | Jan 20, 2021 | Pending |
Array
(
[id] => 18596090
[patent_doc_number] => 20230270881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/794432
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17794432
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/794432 | ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER | Jan 20, 2021 | Pending |
Array
(
[id] => 16854967
[patent_doc_number] => 20210155712
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/153705
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67266
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153705 | Treatment and prevention of cancer using HER3 antigen-binding molecules | Jan 19, 2021 | Issued |
Array
(
[id] => 18195475
[patent_doc_number] => 20230048994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => RECOMBINANT AAV PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 17/793196
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30058
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -98
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793196
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793196 | RECOMBINANT AAV PRODUCTION | Jan 14, 2021 | Pending |
Array
(
[id] => 17170435
[patent_doc_number] => 20210324105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => BISPECIFIC ANTIBODIES AGAINST HER2
[patent_app_type] => utility
[patent_app_number] => 17/149019
[patent_app_country] => US
[patent_app_date] => 2021-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149019
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/149019 | BISPECIFIC ANTIBODIES AGAINST HER2 | Jan 13, 2021 | Abandoned |
Array
(
[id] => 20466847
[patent_doc_number] => 12522880
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-13
[patent_title] => RT-PCR detection method and kit for novel coronavirus
[patent_app_type] => utility
[patent_app_number] => 17/905662
[patent_app_country] => US
[patent_app_date] => 2020-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 7
[patent_no_of_words] => 838
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 165
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905662 | RT-PCR detection method and kit for novel coronavirus | Dec 29, 2020 | Issued |
Array
(
[id] => 18739637
[patent_doc_number] => 20230348599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => METHODS FOR TREATING GLIOBLASTOMA
[patent_app_type] => utility
[patent_app_number] => 17/786917
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -73
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/786917 | METHODS FOR TREATING GLIOBLASTOMA | Dec 16, 2020 | Pending |
Array
(
[id] => 18196930
[patent_doc_number] => 20230050449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/785590
[patent_app_country] => US
[patent_app_date] => 2020-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26203
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785590
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/785590 | METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS | Dec 15, 2020 | Abandoned |